Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Oxford Finance leads Aerovance's $10mm debt sale

Executive Summary

Aerovance (respiratory disorder and eczema compounds) raised $10mm by selling debt to a group led by Oxford Finance and including Silicon Valley Bank and Comerica Bank. The company may draw down another $10mm when it reaches undisclosed corporate milestones. The money will go towards finding a global partner for the recombinant protein Aerovant, in Phase IIa for asthma.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies